Skip to Content
 
Updated : 21 Aug 2020
Oops! Something went wrong while submitting the form.
Laura M Cha crop
Laura M CHA
Chairman - HKEX
Mrs Cha is a member of the Executive Council of the Government of Hong Kong, Chairman of Hong Kong Exchanges and Clearing Ltd and a member of Financial Leaders Forum.

Mrs Cha is an Independent Non-Executive Director of HSBC Holdings plc, the Non-Executive Chairman of The Hongkong and Shanghai Banking Corporation, and a Non-Executive Director of Unilever plc. She is also a Senior International Advisor of Foundation Assets Management Sweden AB and a member of Sotheby’s International Advisory Board. In addition, she is Vice Chairman of the International Advisory Council of the China Securities Regulatory Commission, and a Director of the World Federation of Exchanges.

Mrs Cha became the first, and to-date, the only person outside Mainland China to join the Central Government of the People’s Republic of China at the vice-ministerial rank when she was appointed as Vice Chairman of the China Securities Regulatory Commission in January 2001. She served in that position until September 2004. Mrs Cha worked for Securities and Futures Commission in Hong Kong from 1991 to 2000, becoming its Deputy Chairman in 1998. She was also Chairman of The Financial Services Development Council of Hong Kong from January 2013 to July 2018.   

She was awarded a Silver Bauhinia Star in 2001, a Gold Bauhinia Star in 2009 and the Grand Bauhinia Medal in 2017 by the Hong Kong Government for her public service. 
 
Mrs Cha is a member of the Executive Council of the Government of Hong Kong, Chairman of Hong Kong Exchanges and Clearing Ltd and a member of Financial Leaders Forum.

Mrs Cha is an Independent Non-Executive Director of HSBC Holdings plc, the Non-Executive Chairman of The Hongkong and Shanghai Banking Corporation, and a Non-Executive Director of Unilever plc. She is also a Senior International Advisor of Foundation Assets Management Sweden AB and a member of Sotheby’s International Advisory Board. In addition, she is Vice Chairman of the International Advisory Council of the China Securities Regulatory Commission, and a Director of the World Federation of Exchanges.

Mrs Cha became the first, and to-date, the only person outside Mainland China to join the Central Government of the People’s Republic of China at the vice-ministerial rank when she was appointed as Vice Chairman of the China Securities Regulatory Commission in January 2001. She served in that position until September 2004. Mrs Cha worked for Securities and Futures Commission in Hong Kong from 1991 to 2000, becoming its Deputy Chairman in 1998. She was also Chairman of The Financial Services Development Council of Hong Kong from January 2013 to July 2018.   

She was awarded a Silver Bauhinia Star in 2001, a Gold Bauhinia Star in 2009 and the Grand Bauhinia Medal in 2017 by the Hong Kong Government for her public service. 
 
Read More +
Show Less -
CharlesLi
Charles LI
Chief Executive - HKEX
Charles Li has served as Chief Executive of Hong Kong Exchanges and Clearing Limited (HKEX) since 2010. In this role, Mr. Li has orchestrated some of the most significant strategic initiatives in HKEX’s history, including the acquisition of the London Metal Exchange in 2012, the launch of OTC Clear in 2013, and the introduction of Shanghai-Hong Kong Stock Connect in 2014, Shenzhen-Hong Kong Stock Connect in 2016, and Bond Connect in 2017. He has sought to strengthen Hong Kong’s role as an offshore Renminbi hub and led HKEX’s efforts to reform its listing regime to maintain Hong Kong’s competitiveness and secure its position as a leading IPO centre.

Mr. Li was born in Beijing and grew up in Gansu. Before leaving China for further study, Mr. Li was an offshore oil worker in the North China Sea and then an editor-reporter for China Daily. After completing his Juris Doctor (JD) degree in the US, Mr. Li practiced law in New York with Davis Polk & Wardwell and Brown & Wood. Before joining HKEX, he was Chairman of JP Morgan China, prior to which he was President of Merrill Lynch China.

Mr. Li obtained a BA degree in English literature from Xiamen University in 1984, an MA degree in journalism from the University of Alabama in 1988, and a JD degree from Columbia University School of Law in 1991.

Charles Li has served as Chief Executive of Hong Kong Exchanges and Clearing Limited (HKEX) since 2010. In this role, Mr. Li has orchestrated some of the most significant strategic initiatives in HKEX’s history, including the acquisition of the London Metal Exchange in 2012, the launch of OTC Clear in 2013, and the introduction of Shanghai-Hong Kong Stock Connect in 2014, Shenzhen-Hong Kong Stock Connect in 2016, and Bond Connect in 2017. He has sought to strengthen Hong Kong’s role as an offshore Renminbi hub and led HKEX’s efforts to reform its listing regime to maintain Hong Kong’s competitiveness and secure its position as a leading IPO centre.

Mr. Li was born in Beijing and grew up in Gansu. Before leaving China for further study, Mr. Li was an offshore oil worker in the North China Sea and then an editor-reporter for China Daily. After completing his Juris Doctor (JD) degree in the US, Mr. Li practiced law in New York with Davis Polk & Wardwell and Brown & Wood. Before joining HKEX, he was Chairman of JP Morgan China, prior to which he was President of Merrill Lynch China.

Mr. Li obtained a BA degree in English literature from Xiamen University in 1984, an MA degree in journalism from the University of Alabama in 1988, and a JD degree from Columbia University School of Law in 1991.

Read More +
Show Less -
Zhang Lei
Lei ZHANG
Founder & Chief Executive - Hillhouse Capital
Lei Zhang is the Founder and CEO of Hillhouse Capital Management. In 2005, Mr. Zhang founded Hillhouse, an investment platform that partners with visionary entrepreneurs to build businesses and position them for long-term success. Hillhouse works with companies in the technology, healthcare, consumer and business services sectors.  

Mr. Zhang is deeply involved in educational endeavors. He earned his M.B.A and M.A. in International Relations from Yale University and is a member of the Yale Board of Trustees. He also serves as Chair of the Yale Asia Development Council. Before attending Yale, he earned his B.A. in Economics from the Renmin University of China, where he is Vice Chairman of the Board of Trustees. A recent gift from Mr. Zhang helped establish the Hillhouse Academy, which works with students from universities around China. Mr. Zhang is a founding Trustee of Westlake University, where he is also a founding donor of the Endowment and the Chairman of the Development Council. 

Lei Zhang is the Founder and CEO of Hillhouse Capital Management. In 2005, Mr. Zhang founded Hillhouse, an investment platform that partners with visionary entrepreneurs to build businesses and position them for long-term success. Hillhouse works with companies in the technology, healthcare, consumer and business services sectors.  

Mr. Zhang is deeply involved in educational endeavors. He earned his M.B.A and M.A. in International Relations from Yale University and is a member of the Yale Board of Trustees. He also serves as Chair of the Yale Asia Development Council. Before attending Yale, he earned his B.A. in Economics from the Renmin University of China, where he is Vice Chairman of the Board of Trustees. A recent gift from Mr. Zhang helped establish the Hillhouse Academy, which works with students from universities around China. Mr. Zhang is a founding Trustee of Westlake University, where he is also a founding donor of the Endowment and the Chairman of the Development Council. 

Read More +
Show Less -
Bonnie Y Chan's Photo crop
Bonnie Y CHAN
Head of Listing - HKEX
Bonnie Y Chan is Head of Listing at the Hong Kong Exchanges and Clearing Limited.

Ms. Chan has over 25 years of experience in legal and financial services.  She started her career in private legal practice, worked in a number of investment banks and was a partner at Davis Polk & Wardwell before assuming her current role.

She was Head of IPO of the Listing Division at the Hong Kong Exchanges and Clearing Limited between 2007 and 2010.

Ms. Chan has served on various public service bodies, including the Financial Services Development Council, the Inland Revenue Board, the Standing Committee of Company Law Reform and the Disciplinary Panel of the HKICPA.

Ms. Chan graduated from the University of Hong Kong in 1991 and Harvard Law School in 1993.  She is admitted as a solicitor in Hong Kong and an attorney at law in New York State.
 
Bonnie Y Chan is Head of Listing at the Hong Kong Exchanges and Clearing Limited.

Ms. Chan has over 25 years of experience in legal and financial services.  She started her career in private legal practice, worked in a number of investment banks and was a partner at Davis Polk & Wardwell before assuming her current role.

She was Head of IPO of the Listing Division at the Hong Kong Exchanges and Clearing Limited between 2007 and 2010.

Ms. Chan has served on various public service bodies, including the Financial Services Development Council, the Inland Revenue Board, the Standing Committee of Company Law Reform and the Disciplinary Panel of the HKICPA.

Ms. Chan graduated from the University of Hong Kong in 1991 and Harvard Law School in 1993.  She is admitted as a solicitor in Hong Kong and an attorney at law in New York State.
 
Read More +
Show Less -
190503 Photo (white)  Wilfred Yiu  crop
Wilfred YIU
Managing Director & Head of Markets - HKEX
Wilfred is Managing Director and Head of Markets for Hong Kong Exchanges and Clearing Limited.  Previously, he was Deputy Chief Executive Officer and Chief Operating Officer for Beijing Gao Hua Securities Company Limited, and Chairman of its wholly-owned subsidiary, Qian Kun Futures Co., Ltd.  Prior to that, he was Head of Credit Structured Products for Asia at Goldman Sachs (Asia) L.L.C.  

Wilfred served as a governor for the Board of Dalian Commodity Exchange in China from 2015 to 2017, and is currently an advisor for the Strategic Advisory Committee of Dalian Commodity Exchange.  He is an adjunct professor at the Hong Kong Polytechnic University.

Wilfred earned a Master’s degree in Computer Science from Stanford University and an MBA in Finance from the Stern School of Business at New York University.
 
Wilfred is Managing Director and Head of Markets for Hong Kong Exchanges and Clearing Limited.  Previously, he was Deputy Chief Executive Officer and Chief Operating Officer for Beijing Gao Hua Securities Company Limited, and Chairman of its wholly-owned subsidiary, Qian Kun Futures Co., Ltd.  Prior to that, he was Head of Credit Structured Products for Asia at Goldman Sachs (Asia) L.L.C.  

Wilfred served as a governor for the Board of Dalian Commodity Exchange in China from 2015 to 2017, and is currently an advisor for the Strategic Advisory Committee of Dalian Commodity Exchange.  He is an adjunct professor at the Hong Kong Polytechnic University.

Wilfred earned a Master’s degree in Computer Science from Stanford University and an MBA in Finance from the Stern School of Business at New York University.
 
Read More +
Show Less -
Christina Bao073_bio_white2Mcrop
Christina BAO
Managing Director, Deputy Head of Market Development and Head of Global Issuer Services - HKEX
Ms. Christina Bao, Managing Director, is currently the Deputy Head of Market Development Division and Head of Global Issuer Services at HKEX.  

Ms. Bao joined HKEX in 2016 as the Chief of Staff and report to the CE of HKEX. She was mostly responsible for the general coordination at the senior management, planning and oversight on strategic projects. 

Prior to joining HKEX, Christina held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as Chief of Staff to the Chairman and CEO from 2005 until 2010, in charge of strategic projects, IR, PR. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail E-Finance SBU for Ping An Bank. 

Ms. Bao received her Master of Business Administration (Finance, General) from Peking University.
 
Ms. Christina Bao, Managing Director, is currently the Deputy Head of Market Development Division and Head of Global Issuer Services at HKEX.  

Ms. Bao joined HKEX in 2016 as the Chief of Staff and report to the CE of HKEX. She was mostly responsible for the general coordination at the senior management, planning and oversight on strategic projects. 

Prior to joining HKEX, Christina held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as Chief of Staff to the Chairman and CEO from 2005 until 2010, in charge of strategic projects, IR, PR. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail E-Finance SBU for Ping An Bank. 

Ms. Bao received her Master of Business Administration (Finance, General) from Peking University.
 
Read More +
Show Less -
Michael's photo3M crop
Michael YU
President and CEO - Innovent
Dr. Michael Yu is the founder, chairman and chief executive officer of Innovent Biologics, Inc. He is the chairman of the board of Chinese Antibody Association, the vice chairman of National Technical Committee for Standardization of Biochemical Testing, the vice chairman of Professional Committee of Tumor Immunity and Tumor Biotherapy of Chinese Society of Immunology, the vice chairman of Drug Research and Development Committee of China Pharmaceutical Innovation Promotion Association. He is the Inventor of Oncorine®, Co-inventor and principal developer of Conbercept and TYVYT® (The above three drugs have been on the market and are the class I new drugs). And he has successively won the National Person of the Year in Innovation for Scientific and Technology in 2016, 2017 China Person of the Year in Pharmaceutical Economics, the Most Influential Person of the Year in Life Science in China in 2017 and 2019 “Dushu Lake Cup” most Influential drug research and development leader reward etc.
Dr. Michael Yu is the founder, chairman and chief executive officer of Innovent Biologics, Inc. He is the chairman of the board of Chinese Antibody Association, the vice chairman of National Technical Committee for Standardization of Biochemical Testing, the vice chairman of Professional Committee of Tumor Immunity and Tumor Biotherapy of Chinese Society of Immunology, the vice chairman of Drug Research and Development Committee of China Pharmaceutical Innovation Promotion Association. He is the Inventor of Oncorine®, Co-inventor and principal developer of Conbercept and TYVYT® (The above three drugs have been on the market and are the class I new drugs). And he has successively won the National Person of the Year in Innovation for Scientific and Technology in 2016, 2017 China Person of the Year in Pharmaceutical Economics, the Most Influential Person of the Year in Life Science in China in 2017 and 2019 “Dushu Lake Cup” most Influential drug research and development leader reward etc.
Read More +
Show Less -
Xuefeng Yu Photo crop
Xuefeng YU
Chairman and CEO - CanSino Biologics
Xuefeng Yu, co-founder, Chairman and CEO of CanSino Biologics Inc. He received his master's degree in microbiology from Nankai University in 1988, and his doctor's degree in microbiology from McGill University in Canada in 1997. In 1998, Dr. Yu joined Sanofi Pasteur in Canada and successively held the positions of scientist of product development and the global director of bacterial vaccine development, where he was one of the youngest executives of the Toronto branch.

In 2009, Dr. Yu returned back to China and established CanSino Biologics Inc. (CanSinoBIO), an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. With his 30 years of experience in the development of biological products and enterprise management and operation, CanSinoBIO has currently built the pipelines of 16 vaccine candidates for 13 infectious diseases, including the world's initial vaccine for Ebola virus disease as well as the potential vaccine candidate against COVID-19. 

Dr. Yu also led the construction of the company's first vaccine manufacturing facility, whose design, construction and operation conform to international GMP standards. In 2019, CanSinoBIO was successfully listed on the main board of the Hong Kong stock exchange as well as the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Led by Dr. Yu and his team, CanSinoBIO will continuously launch a number of high-quality and innovative vaccines to the domestic and international markets and thus contributes to the development of global public health.

 
Xuefeng Yu, co-founder, Chairman and CEO of CanSino Biologics Inc. He received his master's degree in microbiology from Nankai University in 1988, and his doctor's degree in microbiology from McGill University in Canada in 1997. In 1998, Dr. Yu joined Sanofi Pasteur in Canada and successively held the positions of scientist of product development and the global director of bacterial vaccine development, where he was one of the youngest executives of the Toronto branch.

In 2009, Dr. Yu returned back to China and established CanSino Biologics Inc. (CanSinoBIO), an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. With his 30 years of experience in the development of biological products and enterprise management and operation, CanSinoBIO has currently built the pipelines of 16 vaccine candidates for 13 infectious diseases, including the world's initial vaccine for Ebola virus disease as well as the potential vaccine candidate against COVID-19. 

Dr. Yu also led the construction of the company's first vaccine manufacturing facility, whose design, construction and operation conform to international GMP standards. In 2019, CanSinoBIO was successfully listed on the main board of the Hong Kong stock exchange as well as the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Led by Dr. Yu and his team, CanSinoBIO will continuously launch a number of high-quality and innovative vaccines to the domestic and international markets and thus contributes to the development of global public health.

 
Read More +
Show Less -
Chen Wen_square
Wen CHEN
Senior Advisor - Tigermed
Wen Chen is currently partner of Yonghua Capital, a leading private equity and VC investment firm overseeing its healthcare investment activities. He was most recently the Senior Vice President of Tigermed Co. Ltd. a publicly traded A-share listed company located in China for its global business development and marketing. Mr. Chen now serves the Company in senior advisor role in business development and strategies. Tigermed is a leading Contract Research Organization in China and Asia Pacific dedicated to provide professional clinical development services to the pharmaceutical and medical device industries. Tigermed debuted its H share on Aug. 7th, the largest IPO event in healthcare sector in Asia Pacific markets. Wen received a Bachelor’s Degree in Biochemistry from Purdue University, West Lafayette, IN and a Master’s Degree in Immunology and Oncology and Business Administration from Washington University in St. Louis and Durham University respectively. He then worked at Amgen research before returning to work in China biotechnology industry since 2000.
Wen Chen is currently partner of Yonghua Capital, a leading private equity and VC investment firm overseeing its healthcare investment activities. He was most recently the Senior Vice President of Tigermed Co. Ltd. a publicly traded A-share listed company located in China for its global business development and marketing. Mr. Chen now serves the Company in senior advisor role in business development and strategies. Tigermed is a leading Contract Research Organization in China and Asia Pacific dedicated to provide professional clinical development services to the pharmaceutical and medical device industries. Tigermed debuted its H share on Aug. 7th, the largest IPO event in healthcare sector in Asia Pacific markets. Wen received a Bachelor’s Degree in Biochemistry from Purdue University, West Lafayette, IN and a Master’s Degree in Immunology and Oncology and Business Administration from Washington University in St. Louis and Durham University respectively. He then worked at Amgen research before returning to work in China biotechnology industry since 2000.
Read More +
Show Less -
Yi Shi crop
Yi SHI
Founding Managing Partner - Lilly Asia Ventures
Yi Shi is the Founder and Managing Partner of Lilly Asia Ventures, a leading biomedical venture capital firm with focus on China. Prior to his current role, Yi worked at Eli Lilly and Company in business development licensing and corporate ventures. His education includes a Ph.D. in Biochemistry and a Master of Business Administration, both from Duke University. He also has a Bachelor of Sciences in Biology from the University of Science and Technology of China. His past and current Board memberships include: Betta Pharmaceuticals, Innovent Biologics, Chipscreen Biosciences, Transcenta, Ansun Biopharma, Elpiscience, and Terns Pharmaceuticals, etc.
Yi Shi is the Founder and Managing Partner of Lilly Asia Ventures, a leading biomedical venture capital firm with focus on China. Prior to his current role, Yi worked at Eli Lilly and Company in business development licensing and corporate ventures. His education includes a Ph.D. in Biochemistry and a Master of Business Administration, both from Duke University. He also has a Bachelor of Sciences in Biology from the University of Science and Technology of China. His past and current Board memberships include: Betta Pharmaceuticals, Innovent Biologics, Chipscreen Biosciences, Transcenta, Ansun Biopharma, Elpiscience, and Terns Pharmaceuticals, etc.
Read More +
Show Less -
Iris Wang Photo (crop)
Iris WANG
Managing Director - OrbiMed

Iris (Ting) Wang, CFA, is a Managing Director for Asia Public Equity. Prior to joining OrbiMed, Ms. Wang was a Director at Credit Suisse and head of Asia and China healthcare research team. Previously, Ms. Wang was a management consultant at McKinsey and A.T. Kearney. Ms. Wang is an M.B.A. degree holder from Columbia Business School and graduated from the Value Investing Program with Dean’s Honor in 2011. She also holds two B.S. degrees in biological science and economics from Peking University.

Iris (Ting) Wang, CFA, is a Managing Director for Asia Public Equity. Prior to joining OrbiMed, Ms. Wang was a Director at Credit Suisse and head of Asia and China healthcare research team. Previously, Ms. Wang was a management consultant at McKinsey and A.T. Kearney. Ms. Wang is an M.B.A. degree holder from Columbia Business School and graduated from the Value Investing Program with Dean’s Honor in 2011. She also holds two B.S. degrees in biological science and economics from Peking University.

Read More +
Show Less -
Romnesh Lamba_new photo 20140218 crop
Romnesh LAMBA
Co-President - HKEX
Mr Lamba is the Co-President at HKEX Group, responsible for overseeing the business and client development of the Group, as well as group strategy and major new HKEX initiatives.  Mr Lamba also directs the activities of the HKEX Innovation Lab.    

Mr Lamba is also a Director of the Stock Exchange of Hong Kong Limited (SEHK) and Hong Kong Futures Exchange Limited, a Board Director of the London Metal Exchange and LME Clear, a member of the HKEX Management Committee and a member of the Supervisory Committee of The Tracker Fund of Hong Kong, a unit trust listed on SEHK.  Mr Lamba joined HKEX in February 2010 and has held various positions in senior management.  In 2012, Mr Lamba and his team were instrumental in leading HKEX’s acquisition of the London Metal Exchange.  Mr Lamba has also been representing HKEX in regular discussions with the company’s institutional shareholders and the investor community. 

Mr Lamba has 30 years of experience in the financial services industry.  Prior to joining HKEX, Mr Lamba was a Senior Advisor to JP Morgan’s Asia Investment Banking and Capital Markets business, with strategic and operating responsibilities from 2008.  He has also worked at Merrill Lynch Asia Pacific for eight years as a Managing Director, where he led the firm’s regional Energy and Power investment banking group and served as the Chief Operating Officer of the firm’s China Origination business.  At Merrill Lynch, Mr Lamba led several landmark listings of Mainland enterprises in Hong Kong.  Prior to moving to Hong Kong in 1994, Mr Lamba worked in the financial services industry in the US for nine years. Mr Lamba holds Master of Business Administration and Bachelor of Science in Economics degrees from The Wharton School of the University of Pennsylvania in the US.
Mr Lamba is the Co-President at HKEX Group, responsible for overseeing the business and client development of the Group, as well as group strategy and major new HKEX initiatives.  Mr Lamba also directs the activities of the HKEX Innovation Lab.    

Mr Lamba is also a Director of the Stock Exchange of Hong Kong Limited (SEHK) and Hong Kong Futures Exchange Limited, a Board Director of the London Metal Exchange and LME Clear, a member of the HKEX Management Committee and a member of the Supervisory Committee of The Tracker Fund of Hong Kong, a unit trust listed on SEHK.  Mr Lamba joined HKEX in February 2010 and has held various positions in senior management.  In 2012, Mr Lamba and his team were instrumental in leading HKEX’s acquisition of the London Metal Exchange.  Mr Lamba has also been representing HKEX in regular discussions with the company’s institutional shareholders and the investor community. 

Mr Lamba has 30 years of experience in the financial services industry.  Prior to joining HKEX, Mr Lamba was a Senior Advisor to JP Morgan’s Asia Investment Banking and Capital Markets business, with strategic and operating responsibilities from 2008.  He has also worked at Merrill Lynch Asia Pacific for eight years as a Managing Director, where he led the firm’s regional Energy and Power investment banking group and served as the Chief Operating Officer of the firm’s China Origination business.  At Merrill Lynch, Mr Lamba led several landmark listings of Mainland enterprises in Hong Kong.  Prior to moving to Hong Kong in 1994, Mr Lamba worked in the financial services industry in the US for nine years. Mr Lamba holds Master of Business Administration and Bachelor of Science in Economics degrees from The Wharton School of the University of Pennsylvania in the US.
Read More +
Show Less -
2019_HKSTP_AlbertWong_crop
Albert WONG
CEO - HKSTP
Albert Wong was appointed CEO of HKSTP in August 2016.  The purpose of Science Park is to accelerate the development of Technology, Innovation and Entrepreneurship of Hong Kong.

Committed to the success of Hong Kong’s future, Albert and his team are responsible for providing world-class services at the Park, to achieve their objective of helping technology companies and talents to realise their commercial potential. These services include technology incubation programmes, tools and research labs for application and product development, early-stage investments, mentoring and business consulting, and connecting Park companies with local industry and trade associations. 

Albert holds an Engineering Degree from the University of Hong Kong and an MBA from the Chinese University of Hong Kong. The 30-plus years of commercial, industrial and leadership roles with various multinationals have provided Albert with the critical appreciation and understanding of building companies, investment networks and solving market needs. The 15 years spent with GE in the US headquarters, Asia-Pacific and China – where he was responsible for M&A, Business Development, Product Management, and Business Operations – were especially significant for him, providing Albert with the knowledge and connections to lead HKSTP today.

Outside of work, Albert actively contributes to the community. He is a member of The Court of The University of Hong Kong and a board member the Hong Kong Sports Institute. An avid runner, Albert regularly takes part in marathons around the world.

 
Albert Wong was appointed CEO of HKSTP in August 2016.  The purpose of Science Park is to accelerate the development of Technology, Innovation and Entrepreneurship of Hong Kong.

Committed to the success of Hong Kong’s future, Albert and his team are responsible for providing world-class services at the Park, to achieve their objective of helping technology companies and talents to realise their commercial potential. These services include technology incubation programmes, tools and research labs for application and product development, early-stage investments, mentoring and business consulting, and connecting Park companies with local industry and trade associations. 

Albert holds an Engineering Degree from the University of Hong Kong and an MBA from the Chinese University of Hong Kong. The 30-plus years of commercial, industrial and leadership roles with various multinationals have provided Albert with the critical appreciation and understanding of building companies, investment networks and solving market needs. The 15 years spent with GE in the US headquarters, Asia-Pacific and China – where he was responsible for M&A, Business Development, Product Management, and Business Operations – were especially significant for him, providing Albert with the knowledge and connections to lead HKSTP today.

Outside of work, Albert actively contributes to the community. He is a member of The Court of The University of Hong Kong and a board member the Hong Kong Sports Institute. An avid runner, Albert regularly takes part in marathons around the world.

 
Read More +
Show Less -
chong1 crop
Chong XU
Principal - F-Prime Capital
Chong is a Principal at F-Prime Capital.  He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China.  Chong currently holds, or has held, Board Director or Observer positions in multiple companies such as Adagene, Citrine Medicine, Geneception, Semma Therapeutics, Innovent Biologics, LenoMed Medical.

Prior to joining F-Prime in 2015, Chong was a management consultant in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore. Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia.  He received his B.S. in biology from Zhejiang University, China.

Chong is a Principal at F-Prime Capital.  He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China.  Chong currently holds, or has held, Board Director or Observer positions in multiple companies such as Adagene, Citrine Medicine, Geneception, Semma Therapeutics, Innovent Biologics, LenoMed Medical.

Prior to joining F-Prime in 2015, Chong was a management consultant in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore. Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia.  He received his B.S. in biology from Zhejiang University, China.

Read More +
Show Less -
Christian_adjusted_resized_crop
Christian HOGG
Executive Director & CEO - Hutchison China MediTech
Mr. Hogg has been an Executive Director and chief executive officer of Chi-Med since 2006. He joined the business in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of our strategy, business and listings. This includes the establishment of our Innovation Platform, Hutchison MediPharma, which now comprises nine drug candidates that are being investigated in clinical studies around the world and a scientific team of about 550 people. Furthermore, Mr. Hogg oversaw the acquisition and operational integration of assets that led to the formation of our Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Prior to joining Chi-Med, Mr. Hogg spent ten years with P&G, starting in the United States in Finance and then Brand Management in the Laundry and Cleaning Products Division. He then moved to China to manage P&G’s detergent business, followed by a move to Brussels to run P&G’s global bleach business.

Mr. Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh in 1987 and an MBA from the University of Tennessee in 1989.
Mr. Hogg has been an Executive Director and chief executive officer of Chi-Med since 2006. He joined the business in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of our strategy, business and listings. This includes the establishment of our Innovation Platform, Hutchison MediPharma, which now comprises nine drug candidates that are being investigated in clinical studies around the world and a scientific team of about 550 people. Furthermore, Mr. Hogg oversaw the acquisition and operational integration of assets that led to the formation of our Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Prior to joining Chi-Med, Mr. Hogg spent ten years with P&G, starting in the United States in Finance and then Brand Management in the Laundry and Cleaning Products Division. He then moved to China to manage P&G’s detergent business, followed by a move to Brussels to run P&G’s global bleach business.

Mr. Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh in 1987 and an MBA from the University of Tennessee in 1989.
Read More +
Show Less -
Gwenael phot_square
Gwénaël MENEUX
General Manager - AstraZeneca Hong Kong & Macau

Mr. Gwénaël Meneux is General Manager of Hong Kong and Macau at AstraZeneca since September 2018. He is a member of AstraZeneca China Senior Management Team since 2016

He was elected at HKAPI Board of Directors in July 2019 and he’s also an active member of the Healthcare Committee of the British Chamber of Commerce

Gwénaël joined AstraZeneca France in February 2009 and acted as Sales Force Excellence Director and Customer Excellence Director successively. He joined AstraZeneca China in September 2016 as Vice President for Commercial Strategy & Excellence

Gwénaël began his career in 1998 at L’Oréal (FMCG division) where he held several sales and marketing positions. Later he joined the Boston Consulting Group as Senior Consultant

Gwénaël holds a MSc in Management from ESSEC Business School (France)

Mr. Gwénaël Meneux is General Manager of Hong Kong and Macau at AstraZeneca since September 2018. He is a member of AstraZeneca China Senior Management Team since 2016

He was elected at HKAPI Board of Directors in July 2019 and he’s also an active member of the Healthcare Committee of the British Chamber of Commerce

Gwénaël joined AstraZeneca France in February 2009 and acted as Sales Force Excellence Director and Customer Excellence Director successively. He joined AstraZeneca China in September 2016 as Vice President for Commercial Strategy & Excellence

Gwénaël began his career in 1998 at L’Oréal (FMCG division) where he held several sales and marketing positions. Later he joined the Boston Consulting Group as Senior Consultant

Gwénaël holds a MSc in Management from ESSEC Business School (France)

Read More +
Show Less -